Arbutus Biopharma
ABUS
Arbutus Biopharma (ABUS) news
Recent news
Arbutus commences US$230 million modified “Dutch auction” tender offer of its common shares at a price not greater than US$5.75 nor less than US$5.00 per share
AInvest Wire · 7d agoArbutus Biopharma Corp: offer purchase price of not less than US$5.00 per share and not more than US$5.75 per share, in cash
AInvest Wire · Aug 21, 2026Arbutus Biopharma Corp: offer is expected to be funded through company's cash on hand
Arbutus Biopharma Corp has announced that the proposed offer is expected to be funded entirely through the company’s existing cash reserves. This approach aligns with the company’s current financial position, which includes a strong liquidity profile. The decision to utilize cash on hand reflects a…
AInvest Wire · Aug 21, 2026Arbutus Biopharma Corp: offer is expected to commence on or about August 24, 2026 and, unless extended or terminated by co
AInvest Wire · Aug 21, 2026Arbutus announces intent to repurchase up to US$230 million of its common shares through modified “Dutch auction” tender offer
AInvest Wire · Aug 21, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.